Cannabidiol and Rifampin Interaction

Understanding the Cannabidiol and Rifampin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Cannabidiol belongs to the Cannabinoid (Anticonvulsant) class and Rifampin belongs to the Rifamycin Antibiotic class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Rifampin makes your body clear cannabidiol much faster than usual, which makes the medicine less effective. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Cannabidiol has 8 total documented interactions on file in this dataset, and Rifampin has 137. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to adjust your dose of cannabidiol to ensure it still works properly while you are taking rifampin. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Cannabidiol or Rifampin based on a web page, speak with your prescriber or pharmacist before making any change.